Skip to content
Menu

Longevity Health Holdings, Inc. XAGE

Full chart Compare
Set alert

Price alert · XAGE

All alert types
0.11 USD +0.01 (+7.69%)

Regular-session close

2.29 +2.18 +1,944.37%

After hours · Nov 19, 4:00 PM ET

0.1041 Day range 0.1041
0.103 52-week range 0.54
YTD
-62.79%
1 year
-74.55%

Fundamental scorecard

3 of 25 checks passed on XAGE’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2025.

Value 0 of 5

  • Failed:P/E below its own 5-year median No profit over the last 12 months, so no P/E.
  • Failed:P/E under 20 No profit over the last 12 months, so no P/E.
  • No data:Price to sales below its own 5-year median Price to sales 0.3. Not enough data to decide.
  • Failed:Price to book below its own 5-year median Shareholders’ equity is negative.
  • Failed:Free cash flow yield above 4% Free cash flow of -3.76M is -1357.6% of the market value.

Growth 1 of 5

  • Passed:Revenue grew over the last year Revenue of 1.05M is +8438.7% on the 12 months before.
  • No data:Revenue grew more than 5% a year over five years Not enough data to decide.
  • Failed:Earnings per share grew over the last year EPS -8.78 against 12.54 in the 12 months before.
  • No data:Earnings per share grew more than 5% a year over five years Not enough data to decide.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 0 of 5

  • Failed:Profitable over the last year Net income of -7.19M over the last 12 months.
  • No data:Profitable in each of the last five fiscal years Not enough data to decide.
  • Failed:Return on equity above 15% Shareholders’ equity is negative.
  • No data:Net margin above its 5-year average Not enough data to decide.
  • Failed:Free cash flow is at least 80% of net income No profit over the last 12 months to compare with.

Financial health 2 of 5

  • Failed:Short-term assets cover short-term liabilities Short-term assets of 3.24M against short-term liabilities of 6.91M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 3.24M against long-term liabilities of 543K.
  • Passed:Net debt under 40% of equity More cash than debt: 1.55M of cash against 371K of debt.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -3.76M is -1013.3% of debt.
  • Failed:Operating profit covers interest at least 3 times Operating profit is -327.2 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What XAGE owns and owes, as of Jun 30, 2025

Short term and long term

Balance sheet · 3.72M of assets

Liabilities exceed assets, so there is no shareholders’ equity to show.

Debt, equity and cash by year

Now: 1.18M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

-131.41 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

3 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C2 / 5 overall

  • DCF 2
  • Return on Equity 5
  • Return on Assets 1
  • Debt / Equity 1
  • P/E 1
  • P/B 1

Valuation

P/E -0.1×
P/S 0.3×
P/B -0.1×
P/FCF -0.2×
EV/EBITDA -0.0×
EV/Sales 0.2×
FCF Yield -645.1%

Profitability

Gross Margin 57.2%
Operating Margin -371.6%
Net Margin -361.0%
ROE 117.7%
ROIC 135.0%
ROA -291.7%

Growth (YoY)

Revenue 3701.4%
Operating Income -42.2%
EPS (diluted) -702.0%
Free Cash Flow 23.8%

Financial Health

Current Ratio 0.2×
Quick Ratio 0.1×
Debt / Equity -0.1×
Net Debt / EBITDA 0.0×
Interest Coverage -390×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31